Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immune clues in rare lung disease explored

NCT ID NCT01208792

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at how the immune system might affect the outlook for people with pulmonary arterial hypertension (PAH). Researchers took blood and skin samples from 629 participants with different types of PAH to search for specific antibodies. The goal was to better understand the role of autoimmunity in the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help identify immune markers that predict disease progression in pulmonary arterial hypertension.
What could go wrong
This is an observational study, not a treatment trial. Findings may not lead to direct therapies or apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

629 people

The number who actually took part.

Started

Jun 2010

Finished

May 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: age over 18 * for PAH patients: pre-capillary PAH evidenced by right-heart catheterization * no associated systemic disease for idiopathic PAH patients * for HIV patients, HIV1 infection confirmed by ELISA and western blot * for patients with porto pulmonary hypertension: evidence by endoscopy of esophageal varices, confirmation of hepatic venous pressure gradient over 5 mmHg by catheterization of the hepatic veins * for patients with congenital heart defect: evidence by imaging of atrial or ventricular septal defect, or patent ductus arterious and confirmed by heart catheterization * patients with SSc will fulfill the American College of Rheumatology (ACR) and the LEROY and MEDSGER criteria * patients with MCTD will fulfill the criteria for MCTD * patients with SLE will fulfill the updated and revised ACR criteria * patients with Sjögren's syndrome will fulfill the American-European consensus group criteria * patients with chronic thromboembolic pulmonary hypertension: Lung scintiscan showing segmental mismatched perfusion defects and confirmation by angiography of the occlusion and the chance of success of endarterectomy according to the location of disease * Signed written informed consent * Patients with health insurance Exclusion Criteria: * age under 18 * pregnant women * absence of written informed consent * associated malignant tumor

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic thromboembolic pulmonary hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

AIDS chronic thromboembolic pulmonary hypertension congenital heart disease connective tissue disorder HIV infectious disease idiopathic pulmonary arterial hypertension mixed connective tissue disease pulmonary arterial hypertension Sjogren syndrome systemic lupus erythematosus systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Congenital heart defect Connective tissue disease HIV infection Pulmonary arterial hypertension Systemic sclerosis

Contacts and locations

Locations

  • Internal Medicine Department, Claude Huriez Hospital

    Lille, 59000, France

  • Internal Medicine Department, Cochin Hospital

    Paris, 75014, France

  • Pneumology Department, Antoine Béclère Hospital

    Clamart, 92000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.